SCHEMBL4777570

SCHEMBL4777570

CS(=O)(=O)N(Cc1ccccc1Cl)c1ccc(N(C=O)CC(O)c2ccccc2)cc1

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.43
ALDH1A1 P00352 1/20 0.43
MAPT P10636 1/20 0.40
CRY1 Q16526 2/20 0.38
CRY2 Q49AN0 2/20 0.38
PER2 O15055 2/20 0.38
CYP51A1 Q16850 1/20 0.37
POLB P06746 2/20 0.37
HPGD P15428 1/20 0.36
MEN1 O00255 1/20 0.35
LMNA P02545 1/20 0.35
TSHR P16473 1/20 0.35
MAPK1 P28482 1/20 0.35
KMT2A Q03164 1/20 0.35
MMP2 P08253 1/20 0.35
MMP9 P14780 1/20 0.35
RORC P51449 1/20 0.35
NR1H2 P55055 1/20 0.35
NR1H3 Q13133 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4777314 0.93 GAA (0.38) GAAALDH1A1MAPTCRY1CRY2
SCHEMBL4777561 0.81 GAA (0.36) GAAALDH1A1MAPTCRY1CRY2
SCHEMBL4775362 0.79 GAA (0.39) GAAALDH1A1MAPTCRY1CRY2
SCHEMBL4771365 0.78 GAA (0.37) GAAALDH1A1MAPTCRY1CRY2
SCHEMBL4777347 0.78 NR1H4 (0.39) GAAALDH1A1MAPTPOLBLMNA
SCHEMBL4771203 0.77 GAA (0.60) GAAALDH1A1MAPTHPGDMEN1
SCHEMBL4777632 0.77 GAA (0.41) GAAALDH1A1MAPTPOLBHPGD
SCHEMBL4792597 0.76 CYP51A1 (0.32) CYP51A1MAPK1NR1H2NR1H3
SCHEMBL14497659 0.74 GAA (0.59) GAAALDH1A1MAPTPOLBHPGD
SCHEMBL4771109 0.74 GAA (0.41) GAAALDH1A1MAPTPOLBHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1942888-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS Cytokinetics, Inc. (US) 2008-07-16 EP claimed
US-20070135435-A1 Certain chemical entities, compositions, and methods CYTOKINETICS, INCORPORATED 2007-06-14 US claimed
WO-2007056078-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS CYTOKINETICS, INC. (US) 2007-05-18 WO claimed
EP-1942888-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS Cytokinetics, Inc. (US) 2008-07-16 EP disclosed
US-20070135435-A1 Certain chemical entities, compositions, and methods CYTOKINETICS, INCORPORATED 2007-06-14 US disclosed
WO-2007056078-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS CYTOKINETICS, INC. (US) 2007-05-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070135435-A1 Certain chemical entities, compositions, and methods KIF5B, KIF2C, PLK1 GAA 466/4885ALDH1A1 2159/4885MAPT 294/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.